BRCA1 and ovarian cancer: The phosphopeptide-binding ability of BRCA1 BRCT is essential for BRCA1’s tumor suppression function (Shakya et al., 2011), where many breast and ovarian cancer related mutations occur (Clapperton et al., 2004, Couch and Weber, 1996, Friedman et al., 1994, Shattuck-Eidens et al., 1995, Shiozaki et al., 2004, Williams et al., 2004).